期刊文献+

疫苗研制及应用的研究现状与展望 被引量:1

The actuality and expectation of the vaccine manufaction and application
下载PDF
导出
摘要 主要从灭活疫苗、减毒活疫苗、重组亚单位疫苗以及核酸疫苗四个方面综述了近年来疫苗研制及应用的现状、存在的问题,并对理想的新一代疫苗作了展望。 The text summarizes the vaccine actuality of manufacture and application, the lying question from inactivated vaccine,attenuated activated vaccine,recombined subunite vaccine,nucleic acid vaccine in the recent years, and expects an ideal vaccine of the new generation.
出处 《延安大学学报(自然科学版)》 2005年第4期78-79,共2页 Journal of Yan'an University:Natural Science Edition
关键词 疫苗研制 应用 问题 现状 vaccine manufacture application question actuality
  • 相关文献

参考文献6

二级参考文献32

  • 1Danielle MCNALLY.METAPHORE ET ARGUMENTATION Pistes de recherche[J].法国研究,1992(1):120-127. 被引量:1
  • 2[1]Hoshino Y,Saif LJ,Kang SY,et al.Identification of group A rotavirus genes associated with virulence of a porcine rotavirus and host range restriction of a human rotavirus in the gnotobiotic piglet model[J].Virology,1995,209(1):274-280.
  • 3[2]Horton H,Vogel TU,Carter DK,et al.Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239[J].J Virol, 2002,76(14):7187-7202.
  • 4[3]Sedegah M,Brice GT,Rogers WO,et al.Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting:characterization of effector and memory CD8(+)-T-cell populations[J]. Infect Immun,2002,70(7):3493-3499.
  • 5[4]Prabakaran I,Menon C,Xu S,et al.Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells[J].Ann Surg Oncol,2002,9(4):411-418.
  • 6[5]Nassi L,Vecchi C.Current state of the world's experiences with vaccination against rubella[J].Ann Sclavo,1975,17(1):17-33.
  • 7[6]Maassab HF,Bryant ML.The development of live attenuated cold-adapted influenza virus vaccine for humans[J].Rev Med Virol,1999 ,9(4):237-244.
  • 8[7]Isaka M,Yasuda Y,Mizokami M,et al.Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant[J].Vaccine,2001,19(11-12):1460-1466.
  • 9[8]Engler OB,Dai WJ,Sette A,et al.Peptide vaccines against hepatitis B virus: from animal model to human studies[J].Mol Immunol, 2001,38(6):457-465.
  • 10[9]Gregersen JP.DNA vaccines[J].Naturwissenschaften,2001,88(12):504-513.

共引文献8

同被引文献13

  • 1庞乐君,刁天喜.痘病毒疫苗载体[J].国外医学(药学分册),2004,31(3):154-157. 被引量:6
  • 2包慧芳,陈创夫,陈福双,任雪艳,王彦芹.转基因植物生产疫苗的研究现状及前景[J].动物科学与动物医学,2004,21(11):61-63. 被引量:4
  • 3刘耀文.病毒载体用于生物防御性疫苗的开发[J].国外医学(药学分册),2006,33(1):46-49. 被引量:2
  • 4寇毅.略述疫苗三次革命[J].中华医史杂志,2006,36(2):104-108. 被引量:7
  • 5姜建波,提金凤,李志杰.新型疫苗研究概况[J].动物医学进展,2007,28(1):96-100. 被引量:4
  • 6NIAID Biodefense Research Agenda for CDC Category A Agents http://www 3. niaid.nih. gov/topicsz%iodefence relatedz%iodefense/PDF/biotresearchagenda.pdf
  • 7National Institutes of Health. Anthrax Vaccine Clinical Trials. http://www.clinicaltrials.gov/ct/gui/show/NCT00114621. 2005-09-09.
  • 8Conlan JW, Shen H, Webb A, et al. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protectlve immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen [J]. Vaccine, 2002,20 (29-30) :3465-3471.
  • 9Wang D, Schmaljohn AL, Raja NU, et al. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses [J].Vaccine, 2006,24(15):2975 -2986.
  • 10Drexler I, Staib C, Kastenmuller W, et al. Identification of vaccinia virus epitope-specific HLA-A * 0201-restricted T cells and comparative analysis of smallpox vaccines [J]. Proc Natl Acad Sci USA, 2003,100(1) :217-222.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部